Biotechnology company Elphogene Inc., which has been founded as a spin-off
from the Genomac Research Institute in Prague, presents the oncoMonitor™ project
for monitoring of circulating tumor DNA (referred to as ctDNA)
in cancer patients.
The Prague-based biotechnological start-up Elphogene has received an initial investment from i&i Prague in order to implement its oncoMonitor™, a liquid biopsy technology into a commercial assay for non-invasive diagnostic monitoring of patients in advanced stages colorectal cancer.
The company has been founded at the beginning of 2019 as a spin-off from the Genomac Research Institute.
Results & Experiences
We have been investigating ctDNA from patients' blood since 2009. We gained experience with patients with various types of cancer (lungs, pancreas, stomach, head and neck), but we found out the best application for colorectal cancer patients for whom oncoMonitor™ was primarily developed.
So far, in several extensive research studies, we have examined more than 500 such patients for the presence of ctDNA, and in at least 30 of them, we conducted long-term postoperative monitoring of ctDNA levels.
News & Media
Clinical application of Elphogene oncoMonitor™ technology was presented at the AMP 2020 Annual Meeting & Expo of the Association for Molecular Pathology (AMP).
Marek Minarik, Ph.D. presented the company Elphogene and the oncoMonitor™ test at the virtual conference of the European Association for Cancer Research.
Marek Minarik, Ph.D. presented a lecture at an online course organized by the Society for Gastrointestinal Oncology.
Marek Minarik, Ph.D. presented the company Elphogene and the oncoMonitor™ test at the annual conference of the American Association for Cancer Research.
Marek Minarik, Ph.D. presented the company Elphogene and the oncoMonitor™ test at a multidisciplinary oncological congress in Prague, Czech Republic.
Marek Minarik, Ph.D. presented the latest data from clinical trials using liquid biopsy based on oncoMonitor™ technology in patients with lung cancer at a conference in Miami, Florida, USA.
Researchers from Elphogene and the Genomac Research Institute, in collaboration with leading Czech oncology centers, have published an article in an international scientific journal.
Clinical application of Elphogene oncoMonitor™ technology will be presented at the AMP 2020 Annual Meeting & Expo of the Association for Molecular Pathology (AMP), which will be held virtually November 16-20.
Elphogene, s.r.o. received grant from the Technology Agency of the Czech Republic for the project “Sample prep system and technology for cancer testing by liquid biopsy”.
The report "Detection of cancer recurrence from blood collection is becoming common reality" about Elphogene, s.r.o. published by CzechSight, s.r.o.
DNA helps diagnose cancer. The key is early detection.